If approved, tofersen would be the first treatment to target a genetic cause of ALS, albeit one ... by 25 January, and Biogen will also have to make the case for its drug at an advisory committee ...

VALOR missed the mark in its first readout in 2021, but according to Biogen the dataset has since improved, showing the drug can slow progression of SOD1 ALS to an extent that is "clinically ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing its first drug asset from the deal. | Just four months after Eli Lilly and ...

Biogen's results beat estimates on strength ... January 6, 2025 Denali Therapeutics' ALS drug fails in mid-to-late stage trial Denali Therapeutics said on Monday its experimental drug failed ...

and ALS drug tofersen. Although Biogen faced an even tougher commercial environment for its multiple sclerosis portfolio outside of leading drug Ocrevus than we had expected in the quarter ...

TOKYO -- New treatments for ALS are progressing little by little, with companies like U.S.-based Biogen and Japan's Otsuka Pharmaceutical working to give hope to patients of the incurable disease.

Ionis licensed this drug to Biogen, which is responsible for commercializing ... FDA in April 2023 for amyotrophic lateral ...